| Ms Dawn Elaine Macmeans, MA CCC-SLP | |
|
15 Sumner Brown Rd, Cumberland, RI 02864-1297 | |
| (401) 333-6352 | |
| (401) 333-1012 |
| Full Name | Ms Dawn Elaine Macmeans |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 15 Sumner Brown Rd, Cumberland, Rhode Island |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215418314 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 5963 (Massachusetts) | Secondary |
| 235Z00000X | Speech-language Pathologist | SP01289 (Rhode Island) | Primary |
| Provider Name | Paragon Outpatient Rehabilitation Services, Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1871867325 PECOS PAC ID: 8022272848 Enrollment ID: O20160728001716 |
News Archive
Bristol-Myers Squibb and Otsuka Pharmaceutical have announced that the U.S. Food and Drug Administration (FDA) has approved Abilify (aripiprazole) for the treatment of acute bipolar mania, including manic and mixed episodes associated with bipolar disorder.
Stopping bleeding, closing wounds, repairing organs—these are everyday challenges in medical and surgical practice. In the journal Angewandte Chemie, French researchers have now introduced a new method that employs gluing by aqueous nanoparticle solutions to effectively control bleeding and repair tissues. In animal tests, their approach proved easy to apply, rapid and efficient even in situations when conventional methods are traumatic or fail.
Around one-fifth of patients consulting their primary care physician for acute cough could have undiagnosed asthma or chronic obstructive pulmonary disease, show the results of a pan-European study.
A new device developed by UCLA engineers and doctors eventually help scientists study the development of disease, enable them to capture improved images of the inside of cells and lead to other improvements in medical and biological research.
Sanford Heart Hospital has started a clinical trial to study a dissolving device in patients with coronary artery disease. The ABSORB III clinical trial will investigate the safety and effectiveness of the Absorb Bioresorbable Vascular Scaffold (BVS) device, manufactured by global health care company Abbott.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Dawn Elaine Macmeans, MA CCC-SLP 15 Sumner Brown Rd, Cumberland, RI 02864-1297 Ph: (401) 333-6352 | Ms Dawn Elaine Macmeans, MA CCC-SLP 15 Sumner Brown Rd, Cumberland, RI 02864-1297 Ph: (401) 333-6352 |
News Archive
Bristol-Myers Squibb and Otsuka Pharmaceutical have announced that the U.S. Food and Drug Administration (FDA) has approved Abilify (aripiprazole) for the treatment of acute bipolar mania, including manic and mixed episodes associated with bipolar disorder.
Stopping bleeding, closing wounds, repairing organs—these are everyday challenges in medical and surgical practice. In the journal Angewandte Chemie, French researchers have now introduced a new method that employs gluing by aqueous nanoparticle solutions to effectively control bleeding and repair tissues. In animal tests, their approach proved easy to apply, rapid and efficient even in situations when conventional methods are traumatic or fail.
Around one-fifth of patients consulting their primary care physician for acute cough could have undiagnosed asthma or chronic obstructive pulmonary disease, show the results of a pan-European study.
A new device developed by UCLA engineers and doctors eventually help scientists study the development of disease, enable them to capture improved images of the inside of cells and lead to other improvements in medical and biological research.
Sanford Heart Hospital has started a clinical trial to study a dissolving device in patients with coronary artery disease. The ABSORB III clinical trial will investigate the safety and effectiveness of the Absorb Bioresorbable Vascular Scaffold (BVS) device, manufactured by global health care company Abbott.
› Verified 3 days ago
Ms. Cheryl A Webster, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 21 Tallyho Rd, Cumberland, RI 02864 Phone: 401-743-1554 | |
Miss Katherine Herbert, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 15 Sumner Brown Rd, Cumberland, RI 02864 Phone: 401-333-6352 | |
Brooke Mackenzie Taylor, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 30 Martin St Ste 4b, Cumberland, RI 02864 Phone: 401-228-2186 | |
Valentina Karnaukh, M.S., CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 15 Summer Brown Road, Cumberland, RI 02864 Phone: 401-333-6352 | |
Marley Dutcher, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13 Vincent Way, Cumberland, RI 02864 Phone: 401-225-7728 | |
Briana Therien, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 100 Chambers St, Cumberland, RI 02864 Phone: 401-724-7500 |